Drug intelligence / Profile preview

11h

Development stage: Preclinical
Lead developer: Goldenrod Therapeutics
Modality: Small Molecules

Overview

11h is a small molecule phosphodiesterase (PDE) inhibitor being developed by Goldenrod Therapeutics for the treatment of Multiple Sclerosis and Epilepsy. By inhibiting PDE enzymes, 11h prevents the degradation of cyclic nucleotides such as cAMP and cGMP, which play critical roles in regulating neuroinflammation and neuronal signaling. The drug is currently in the preclinical stage, having demonstrated in vivo activity in models of Multiple Sclerosis and remaining in the discovery phase for Epilepsy.

Other names: 11H-Dibenzo(b,E)(1,4)diazepin-11-one, 8-chloro-5,10-dihydro

Targets

PDE4APDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)PDE4C (Phosphodiesterase 4C)PDE4D (Phosphodiesterase 4D)

Beyond the preview

Go deeper on 11h.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 11h.

Explore the full profile